dbo:abstract
|
- Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Tremelimumab was approved for unresectable hepatocellular carcinoma medical use in the United States in October 2022. (en)
|
dbo:alternativeName
| |
dbo:casNumber
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:kegg
| |
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 12428 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:c
| |
dbp:caption
|
- Fab fragment of tremelimumab binding CTLA-4 . From PDB entry . (en)
|
dbp:casNumber
| |
dbp:chemspiderid
| |
dbp:dailymedid
| |
dbp:drugbank
| |
dbp:h
| |
dbp:iupharLigand
| |
dbp:kegg
| |
dbp:legalUs
| |
dbp:mabType
| |
dbp:n
| |
dbp:o
| |
dbp:routesOfAdministration
| |
dbp:s
| |
dbp:source
| |
dbp:synonyms
|
- tremelimumab-actl, ticilimumab, CP-675, CP-675,206 (en)
|
dbp:target
| |
dbp:tradename
| |
dbp:type
| |
dbp:unii
| |
dbp:verifiedfields
| |
dbp:verifiedrevid
| |
dbp:watchedfields
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Tremelimumab was approved for unresectable hepatocellular carcinoma medical use in the United States in October 2022. (en)
|
rdfs:label
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |